Novo Nordisk's Chairman Gains Unprecedented Control After Major Board Overhaul

Novo Nordisk just got a boardroom makeover, and it's shaking up power dynamics big time. The Novo Nordisk Foundation, which owns over 75% of voting rights, has driven out key independent directors and the old chairman, installing its own chair, Lars Rebien Sørensen, as both foundation head and company board chairman-a first in the drugmaker's history.

Sørensen, who steered Novo Nordisk as CEO from 2000 to 2016, now wields remarkable influence, essentially holding 'carte blanche' over corporate decisions. This move comes amid a tough year for Novo, once Europe's most valuable firm thanks to its obesity drug Wegovy. Sales growth has stalled, and U.S. competition, especially from Eli Lilly, has surged, denting investor confidence.

The newly appointed CEO, Mike Doustdar, faces the daunting task of reversing these trends amid sweeping restructuring, including 9,000 planned job cuts. His arrival was marked by a profit warning that sent shares diving 30%, underscoring the uphill battle ahead.

The dual chairman role immediately raises governance eyebrows. Danish shareholder advocates warn that foundation and company roles need clearer separation to maintain checks and balances. With Sørensen's extended tenure of 2-3 years planned, this blend of leadership tests the balance of influence - especially given the Foundation's previously stated aim of keeping an arm's-length oversight.

Some shareholders acknowledge the prior board faltered in addressing competitive threats and operational missteps, such as inadequate Wegovy manufacturing capacity and underestimating U.S. consumer segments. In this light, the tightened grip might buy the company some short-term stability.

Still, critics worry about concentration of power. The Foundation's assertiveness disrupts typical governance norms where foundations usually step back from daily management, raising the question: does this activist-like stance signify a necessary course correction, or a risky erosion of board independence?

Market reaction has been mixed. Novo Nordisk's shares continue to languish, down around 5% since the leadership shuffle and roughly two-thirds off their 2024 peak. Investors are clearly weighing whether Sørensen's stewardship can steer the heavyweight pharma firm back to its winning ways.

For now, it's a high-stakes boardroom drama unfolding, spotlighting the challenges entrenched founders face in making course corrections. Whether this centralized command sparks a turnaround or creates corporate friction will be a story to watch - or not, if history repeats that boardroom power grabs rarely heal without scars.